Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia, Ventilator-Associated
Conditions
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Abdominal Abscess, Bacterial Infections
Trial Timeline
Oct 1, 2007 → Nov 1, 2008
NCT ID
NCT00515034About Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem is a phase 2 stage product being developed by Johnson & Johnson for Pneumonia, Ventilator-Associated. The current trial status is completed. This product is registered under clinical trial identifier NCT00515034. Target conditions include Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00515034 | Phase 2 | Completed |
Competing Products
20 competing products in Pneumonia, Ventilator-Associated
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAL02 Low-dose + CAL02 High-dose + Placebo | Combioxin | Phase 1 | 25 |
| tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| Cefiderocol + Best Available Therapy | Shionogi | Phase 3 | 77 |
| Cefiderocol + Meropenem + Linezolid | Shionogi | Phase 3 | 77 |
| Cefiderocol + Standard of Care Antibiotic | Shionogi | Phase 1 | 33 |
| ONO-5046Na + ONO-5046Na | Ono Pharmaceutical | Phase 2 | 52 |
| doripenem | Johnson & Johnson | Approved | 85 |
| levofloxacin; imipenem/cilastitin | Johnson & Johnson | Phase 3 | 77 |
| levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| levofloxacin | Johnson & Johnson | Phase 2/3 | 65 |
| Levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| doripenem | Johnson & Johnson | Phase 3 | 77 |
| doripenem | Johnson & Johnson | Phase 3 | 77 |
| Doripenem + Imipenem-Cilastatin + Placebo | Johnson & Johnson | Phase 3 | 77 |
| HRS-8427 + Meropenem | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Tedizolid phosphate + Linezolid | Merck | Phase 3 | 77 |
| Ceftolozane/Tazobactam + Piperacillin/Tazobactam | Merck | Phase 3 | 77 |
| IMI/REL FDC + PIP/TAZ FDC + Linezolid | Merck | Phase 3 | 77 |